{"ctNumber":"2025-521385-10-00","ctStatus":"Authorised","decisionDate":"2025-10-21T10:58:52.882","publishDate":"2025-10-22T03:31:39.101141607","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":98233,"rowSubjectCount":0,"products":[{"id":405939,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10825MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"TAMOXIFEN","pharmForm":"TABLET","activeSubstanceName":"TAMOXIFEN","euSubstNumber":"SUB10825MIG","productSubstances":[{"substancePk":"330598","actSubstOrigin":"Chemical","actSubstName":"TAMOXIFEN","substanceEvCode":"SUB10825MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"40","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"40","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"oncolytic agents","scientificProductEvCode":"SUB10825MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"TAMOXIFEN","jsonActiveSubstanceNames":"tamoxifen"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery","fullTitleTranslations":[{"id":7751453,"uuid":"7fe60244-d5ac-4b17-a8a7-fae655709660","attributeTranslation":"ENDO-67 project: Het onderzoeken van endocriene therapiegerelateerde vraagstellingen op basis van Ki67-veranderingen in het 'window-of-opportunity' voorafgaand aan een borstoperatie","language":37,"languageDescription":"Dutch (Netherlands)"}],"publicTitle":"ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery","publicTitleTranslations":[{"id":7751461,"uuid":"505f73b7-daf5-4570-9a2d-b4f3971195fe","attributeTranslation":"ENDO-67 project: Het onderzoeken van endocriene therapiegerelateerde vraagstellingen op basis van Ki67-veranderingen in het 'window-of-opportunity' voorafgaand aan een borstoperatie","language":37,"languageDescription":"Dutch (Netherlands)"}],"secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":true,"justificationOfLowIntervention":"In this study we want to investigate whether we can predict insensitivity of endocrine therapy with the use of Ki67. Therefore, the already authorized tamoxifen, is used as a first type of endocrine therapy to investigate whether we can selected which patient will benefit from this medication. Tamoxifen is used in an authorized dose and there will be only one extra biopsy and blood draw taken comparing to usual care","trialPhase":"6","trialCategory":"3","justificationForTrialCategory":"In this study we want to investigate whether we can predict insensitivity of endocrine therapy with the use of Ki67. Therefore, the already authorized tamoxifen, is used as a first type of endocrine therapy to investigate whether we can selected which patient will benefit from this medication","trialCategoryId":88980},"medicalCondition":{"partIMedicalConditions":[{"id":101367,"medicalCondition":"Breast cancer","medicalConditionTranslations":[{"id":7751437,"uuid":"ab0ef581-49e4-4759-adc2-6244431eabf0","attributeTranslation":"Mammacarcinoom/borstkanker","language":37,"languageDescription":"Dutch (Netherlands)"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"5","trialScopeId":293943},{"code":"3","trialScopeId":293941},{"code":"11","trialScopeId":293942},{"code":"6","trialScopeId":293940}],"mainObjective":"1. Can steady-state levels of endoxifen be achieved within three (rather than twelve) weeks using the PK model-derived tamoxifen loading schedule?\n2. Can ER-pathway inactivity, measured by percentage Ki67 before and after treatment in ER positive tumours, reliable predict tamoxifen insensitivity?\n3. What is de correlation between intratumoral endoxifen levels and Ki67 response?","mainObjectiveTranslations":[{"id":7751460,"uuid":"fe7e4d61-62b1-434a-a369-60c466b8fe03","attributeTranslation":"1. Kan met het op farmacokinetische modellen gebaseerde oplaadschema voor tamoxifen een steady-state spiegel van endoxifen worden bereikt binnen drie weken in plaats van twaalf weken?\n\n2. Kan inactiviteit van de oestrogeenreceptorroute, gemeten aan de hand van het percentage Ki67 vóór en na behandeling bij ER-positieve tumoren, betrouwbaar voorspellen of er sprake is van tamoxifenongevoeligheid?\n\n3. Wat is de correlatie tussen intratumorale endoxifenspiegels en de Ki67-respons?","language":37,"languageDescription":"Dutch (Netherlands)"}],"secondaryObjectives":[{"id":338193,"number":1,"secondaryObjective":"What is the concordance between Ki67 percentage measured after three weeks of tamoxifen treatment (biopsy) and the resection specimen?","secondaryObjectiveTranslations":[{"id":7751462,"uuid":"a1b1947a-1121-411c-9702-f1ae88839831","attributeTranslation":"Wat is de overeenstemming tussen het Ki67-percentage gemeten na drie weken tamoxifenbehandeling (biopt) en het resectiemateriaal?","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":338194,"number":2,"secondaryObjective":"What is the effect of tamoxifen on estradiol and progesterone levels in pre- and postmenopausal women?","secondaryObjectiveTranslations":[{"id":7751463,"uuid":"eddd2400-c623-4a45-a7dd-a514c87770eb","attributeTranslation":"Wat is het effect van tamoxifen op de oestradiol- en progesteronspiegels bij pre- en postmenopauzale vrouwen?","language":18,"languageDescription":"Dutch"}]},{"id":338195,"number":3,"secondaryObjective":"What is the concordance between Ki67 percentage measured by the pathologist versus an artificial intelligence (AI) algorithm","secondaryObjectiveTranslations":[{"id":7751464,"uuid":"a7ddc9bb-fcfe-4367-bbcd-15230ed42c33","attributeTranslation":"Wat is de overeenstemming tussen het Ki67-percentage gemeten door de patholoog en dat bepaald met een algoritme door kunstmatige intelligentie (AI)?","language":18,"languageDescription":"Dutch"}]},{"id":338196,"number":4,"secondaryObjective":"What is the difference in side effects experiences after three weeks using the loading schedule of tamoxifen compared to after 12 weeks of continuous use of 20mg using the FACT-ES questionnaire","secondaryObjectiveTranslations":[{"id":7751465,"uuid":"3d80c146-eb79-4cc4-b150-80fa5d789330","attributeTranslation":"Wat is het verschil in ervaren bijwerkingen na drie weken gebruik van het oplaadschema van tamoxifen vergeleken met na twaalf weken continu gebruik van 20 mg, gemeten met de FACT-ES vragenlijst?","language":18,"languageDescription":"Dutch"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":649832,"number":1,"principalInclusionCriteria":"Patients with treatment naïve, ≥cT1c ER+, Her2-  primary breast cancer (tumor still in situ) with a Ki-67 ≥10%","principalInclusionCriteriaTranslations":[{"id":7751454,"uuid":"ba4d0e92-b7cd-4f60-a330-8ef5aa619a43","attributeTranslation":"Patiënten met een onbehandelde, ≥cT1c ER-positieve, Her2-negatieve primaire borstkanker (tumor nog in situ) met een Ki-67 van ≥10%","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":649833,"number":2,"principalInclusionCriteria":"Age older than 18 year","principalInclusionCriteriaTranslations":[{"id":7751455,"uuid":"856382d5-5e66-4458-9662-d3dc4ce894ed","attributeTranslation":"Leeftijd ouder dan 18 jaar.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":649834,"number":3,"principalInclusionCriteria":"An indication for postoperatively endocrine treatment","principalInclusionCriteriaTranslations":[{"id":7751456,"uuid":"900c6bf0-ad00-4d97-a0cc-211a56b5db71","attributeTranslation":"Een indicatie voor postoperatieve endocriene therapie.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":649835,"number":4,"principalInclusionCriteria":"WHO performance status 0-2","principalInclusionCriteriaTranslations":[{"id":7751457,"uuid":"447098b9-00ff-497b-82f0-59533da4a94e","attributeTranslation":"WHO performance status 0 tot 2","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":649836,"number":5,"principalInclusionCriteria":"The primary breast tumor should be amendable for multiple biopsies","principalInclusionCriteriaTranslations":[{"id":7751458,"uuid":"a668437f-43ab-476b-9bf1-dd77ba596cba","attributeTranslation":"De primaire borsttumor moet geschikt zijn voor het afnemen van meerdere biopten.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":649837,"number":6,"principalInclusionCriteria":"Specific for tamoxifen: Indication for adjuvant tamoxifen treatment","principalInclusionCriteriaTranslations":[{"id":7751459,"uuid":"83a33f83-23f9-4574-a357-badd03d255d3","attributeTranslation":"Specifiek voor tamoxifen: Indicatie voor adjuvante behandeling met tamoxifen.","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"principalExclusionCriteria":[{"id":1117266,"number":1,"principalExclusionCriteria":"Women who are pregnant or breast feeding","principalExclusionCriteriaTranslations":[{"id":7751445,"uuid":"facf4f8c-62ee-48f3-a280-04949429b2fc","attributeTranslation":"Vrouwen die zwanger zijn of borstvoeding geven.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117267,"number":2,"principalExclusionCriteria":"Patients in whom neoadjuvant chemotherapy is indicated and delay is not desirable","principalExclusionCriteriaTranslations":[{"id":7751446,"uuid":"324673cc-a1d1-401f-bbbd-954bd02dca81","attributeTranslation":"Patiënten bij wie neoadjuvante chemotherapie is geïndiceerd en uitstel van behandeling niet wenselijk is.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117268,"number":3,"principalExclusionCriteria":"Patients with known alcoholism, drug addiction and/or psychiatric of physiological condition which in the opinion of the investigator would impair treatment compliance","principalExclusionCriteriaTranslations":[{"id":7751447,"uuid":"87b52be8-4d74-4a5f-874d-8b9a86b0130e","attributeTranslation":"Patiënten met bekende alcoholverslaving, drugsverslaving en/of een psychiatrische of lichamelijke aandoening die volgens de onderzoeker de therapietrouw zou kunnen belemmeren.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117269,"number":4,"principalExclusionCriteria":"Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of endocrine treatment or puts the patient at high risk for treatment related complications.","principalExclusionCriteriaTranslations":[{"id":7751448,"uuid":"0f79d8c8-524b-491e-96e5-fa27a2510892","attributeTranslation":"Aantoonbaar bewijs van een andere ziekte, neurologische of metabole stoornis, bevinding bij het lichamelijk onderzoek of bloedonderzoek die een redelijke verdenking geven op een aandoening die het gebruik van endocriene therapie contra-indiceert of de patiënt een verhoogd risico geeft op therapiegerelateerde complicaties.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117270,"number":5,"principalExclusionCriteria":"Specific for tamoxifen: Endometrial cancer (diagnosis < 3 years ago)","principalExclusionCriteriaTranslations":[{"id":7751449,"uuid":"673975a9-bb59-4cf6-b77b-12ca1ab5a520","attributeTranslation":"Specifiek voor tamoxifen: Endometriumcarcinoom (gediagnosticeerd minder dan 3 jaar geleden).","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117271,"number":6,"principalExclusionCriteria":"Specific for tamoxifen: •\tUse of strong CYP2D6-inhibitors without the possibility to stop this medication","principalExclusionCriteriaTranslations":[{"id":7751450,"uuid":"1717de85-5b96-4302-8114-ddc81d3736ef","attributeTranslation":"Specifiek voor tamoxifen: Gebruik van sterke CYP2D6-remmers zonder mogelijkheid om deze medicatie te staken.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117272,"number":7,"principalExclusionCriteria":"Specific for tamoxifen: •\tConcomitant use of over-the-counter-drugs, herbal or homeopathic remedies which (may) interfere with tamoxifen and not willing to stop such as (but not limited to ) St. John’s Wort, curcuma/piperine","principalExclusionCriteriaTranslations":[{"id":7751451,"uuid":"12b9ac43-2fbe-43f8-8614-37a650a554fd","attributeTranslation":"Specifiek voor tamoxifen: Gelijktijdig gebruik van vrij verkrijgbare middelen, kruiden- of homeopathische preparaten die (mogelijk) de werking van tamoxifen beïnvloeden en waarbij de patiënt niet bereid is deze te stoppen, zoals (maar niet beperkt tot) sint-janskruid, kurkuma/piperine.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1117273,"number":8,"principalExclusionCriteria":"Specific for tamoxifen: Known poor metabolizer of CYP2D6","principalExclusionCriteriaTranslations":[{"id":7751452,"uuid":"6966e4d7-f664-4af4-8038-9fe1942bac4a","attributeTranslation":"Specifiek voor tamoxifen: Bekende slechte metaboliseerder van CYP2D6.","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"endPoint":{"primaryEndPoints":[{"id":760947,"number":1,"endPoint":"Endoxifen levels after three months of continuous use of 20mg (standard dose) of tamoxifen","isPrimary":true,"endPointTranslations":[{"id":7751438,"uuid":"5d52310a-dc9a-4a93-b194-4a68f4a84545","attributeTranslation":"Endoxifen levels 3 maanden na continue gebruik van 20mg (standaard dosering) tamoxifen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":760948,"number":2,"endPoint":"Tamoxifen resistance defined as Ki67 >10% after three weeks of tamoxifen use according to an adequate dosing schedule","isPrimary":true,"endPointTranslations":[{"id":7751439,"uuid":"81359917-cc24-4d6c-a4d3-794b8e1f47a7","attributeTranslation":"Tamoxifen resistentie gedefinieerd als een Ki67 van >10% na 3 weken van tamoxifen gebruik bij een adequaat doseringsschema","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":760949,"number":3,"endPoint":"Intratumoral endoxifen levels after three weeks and Ki67 response defined as difference between Ki67 percentage for and Ki67 percentage after three weeks of tamoxifen according to an adequate dosing schedule","isPrimary":true,"endPointTranslations":[{"id":7751440,"uuid":"65f876f1-9ec5-4aaf-a285-753068d9c632","attributeTranslation":"Intratumorale endoxifen levels na 3 weken en Ki67 respons gedefinieerd als een verschil tussen het Ki67 percentage voor en het Ki67 percentage na 3 weken of tamoxifen gebruik met een adequaat doseringsschema","language":37,"languageDescription":"Dutch (Netherlands)"}]}],"secondaryEndPoints":[{"id":760950,"number":1,"endPoint":"Ki67 percentages on tumor material","isPrimary":false,"endPointTranslations":[{"id":7751441,"uuid":"7246e542-ebb8-41b8-ae80-c78f5a7f8d52","attributeTranslation":"Ki67 percentage op tumor materiaal","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":760951,"number":2,"endPoint":"Levels on estradiol and progesterone in blood after three weeks and three months of tamoxifen treatment","isPrimary":false,"endPointTranslations":[{"id":7751442,"uuid":"8174ebf5-ffaa-4d8b-9564-09c5a51b139a","attributeTranslation":"Oestradiol en progesteron levels in het bloed na 3 weken en 3 maanden gebruik van tamoxifen","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":760952,"number":3,"endPoint":"Ki67 percentages on tumor material measured by the pathologist and measured by an AI algorithm","isPrimary":false,"endPointTranslations":[{"id":7751443,"uuid":"078bfba5-5ac0-4cd3-b2d3-33a8ca5757ae","attributeTranslation":"Ki67 percentage op tumor materiaal gemeten door de patholoog en gemeten door een kunstmatig intelligent algoritme.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":760953,"number":4,"endPoint":"Change in scores of the FACT-ES questionnaire","isPrimary":false,"endPointTranslations":[{"id":7751444,"uuid":"b076770a-002b-480e-8773-b4b5f3ac5fb4","attributeTranslation":"Verandering in de score van de FACT-ES vragenlijst","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"trialDuration":{"estimatedEndDate":"2030-11-01","estimatedRecruitmentStartDate":"2025-11-01"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":268875,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":268874,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":142570,"businessKey":"1","title":"The ENDO-67 project","description":"Investigating endocrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery","blindingMethodCode":"3","blindedRoles":[],"armDetails":[],"allocationMethod":"3"}]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-20","conclusionDate":"2025-10-20","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":101367,"medicalCondition":"Breast cancer","isConditionRareDisease":false}],"sponsors":[{"id":110043,"primary":true,"publicContacts":[{"id":324206,"type":"Public","functionalName":"M. van Rosmalen","functionalEmailAddress":"m.vanrosmalen@erasmusmc.nl","telephone":"0107041733","organisation":{"id":752811,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":324207,"type":"Scientific","functionalName":"M. van Rosmalen","functionalEmailAddress":"m.vanrosmalen@erasmusmc.nl","telephone":"0107041733","organisation":{"id":752811,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":752811,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"},"addresses":[{"id":714563,"organisation":{"id":752811,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008976","organisationLocationStatus":"Active"},"address":{"addressId":782598,"oneLine":"Dr. Molewaterplein 40","addressLine1":"Dr. Molewaterplein 40","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rotterdam","postcode":"3015 GD","country":2029,"countryName":"Netherlands"},"isBusinessKeyValidated":true,"businessKey":"ORG-100008976"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"3","trialCategoryJustificationComment":"In this study we want to investigate whether we can predict insensitivity of endocrine therapy with the use of Ki67. Therefore, the already authorized tamoxifen, is used as a first type of endocrine therapy to investigate whether we can selected which patient will benefit from this medication","partOneTherapeuticAreas":[{"id":953657,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":305887,"comments":"TAMOXIFEN","productRoleCode":"1","productRoleName":"Test","products":[{"id":405939,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10825MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"TAMOXIFEN","pharmForm":"TABLET","activeSubstanceName":"TAMOXIFEN","euSubstNumber":"SUB10825MIG","productSubstances":[{"substancePk":"330598","actSubstOrigin":"Chemical","actSubstName":"TAMOXIFEN","substanceEvCode":"SUB10825MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"40","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"40","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"oncolytic agents","scientificProductEvCode":"SUB10825MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"TAMOXIFEN","jsonActiveSubstanceNames":"tamoxifen"}]}],"isLowIntervention":true},"authorizedPartsII":[{"id":243867,"mscId":49899,"mscInfo":{"id":49899,"clinicalTrialId":22915,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2025-09-24","toDate":"2025-09-24","isProposedRms":true,"countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2025-10-21","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":87180,"mscId":49899,"trialStatus":"Under evaluation","trialStatusDate":"2025-07-09T13:07:29.769"},{"id":106665,"mscId":49899,"trialStatus":"Authorised","trialStatusDate":"2025-10-21T10:58:52.552"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-20","decision":"authorized","decisionDate":"2025-10-21"},"decisionDate":"2025-10-21","recruitmentSubjectCount":175,"trialSites":[{"id":1657558,"organisationAddressInfo":{"id":594044,"organisation":{"id":626845,"type":"Health care","typeCode":"2","name":"Erasmus MC","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000010750","organisationLocationStatus":"Active"},"address":{"addressId":641056,"oneLine":"Dr Molewaterplein 40","addressLine1":"Dr Molewaterplein 40","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rotterdam","postcode":"3015 GD","country":2029,"countryName":"Netherlands"},"phone":"0031107041733","email":"a.jager@erasmusmc.nl","isBusinessKeyValidated":false,"businessKey":"ORL-000010750"},"personInfo":{"id":1842738,"firstName":"Agnes","lastName":"Jager","telephone":"0031107041733","email":"a.jager@erasmusmc.nl","title":"2"},"departmentName":"Medical oncology"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":49397,"type":"INITIAL","status":"Authorised","ctNumber":"2025-521385-10-00","trialStatus":"Authorised","submissionDate":"2025-07-09","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-20"},"partIIInfo":[{"id":243867,"mscId":49899,"mscInfo":{"id":49899,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-20","decision":"authorized","decisionDate":"2025-10-21","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2025-10-21"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-10-21","ctMSCsByApplication":[{"id":49899,"mscName":"Netherlands","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":94543,"applicationId":49397,"mscId":49899,"mscName":"Netherlands","decisionDate":"2025-10-21T10:58:52.882","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":243867,"part1Id":98233,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"6028266f-d403-42aa-b149-9dd30f47b0e3","productRoleGroupId":305887}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Netherlands","mscId":49899,"firstDecisionDate":"2025-10-21T10:58:52.882","lastDecisionDate":"2025-10-21T10:58:52.882","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":49899,"mscName":"Netherlands","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1 Protocol 2025-521385-10","uuid":"4ef3a692-2650-4ef9-bad6-3b65aa631de1","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":98233,"manualVersion":"1","systemVersion":"3"},{"title":"D1_Protocol 2025-521385-10 synopsis Dutch","uuid":"4c336478-2163-43a4-8d72-d9364cdacf0d","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":98233,"manualVersion":"1","systemVersion":"1"},{"title":"E2_SmPC Tamoxifen","uuid":"6028266f-d403-42aa-b149-9dd30f47b0e3","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":305887,"manualVersion":"1.3.1.1","systemVersion":"1"},{"title":"K1_Recruitment arrangements","uuid":"aede1443-4896-408d-8391-f695e0d9c835","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":243867,"manualVersion":"1.1","systemVersion":"3"},{"title":"L1 SIS and ICF adults ENDO67 version 1 09072025","uuid":"702a314a-edd0-4562-974d-0715de0a47bb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":243867,"manualVersion":"1.2","systemVersion":"3"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}